Search clinical trials for: Fampyra

Total 17 results

Courtney Casserly

Recruiting

Fampridine-SR and Optic Neuritis Recovery (FAMP-ON)

Optic Neuritis

Canada
University College Dublin

Completed

A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

Ireland
Centre Hospitalier Universitaire de Besancon

Completed

Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. (FAMPISEP)

Multiple Sclerosis

France
Biogen

Completed

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice (LIBERATE)

Multiple Sclerosis

France, Spain, Germany, Netherlands, Argentina, Czechia, Israel, Portugal, United Arab Emirates, Canada, Norway, Lebanon, Ireland
Clinique Neuro-Outaouais
CogState Ltd.

Completed

Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients

Multiple Sclerosis

Canada
University of Southern Denmark
Biogen; Region of Southern Denmark

Completed

FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (FAME)

Multiple Sclerosis

Denmark
University of Southern Denmark
Biogen; Region of Southern Denmark

Completed

Resistance Training and Amino Pyridine in Multiple Sclerosis (RETRAP)

Multiple Sclerosis

Denmark
Biogen

Completed

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (ENHANCE)

Multiple Sclerosis

United States, Finland, Italy, United Kingdom, Bulgaria, Serbia, Russian Federation, Lithuania, Poland, Czech Republic, Netherlands
Biogen

Completed

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (MOTION - JAPAN)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive

Japan
Biogen

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (ENABLE)

Multiple Sclerosis

France, Italy, United Kingdom, Germany, Australia, Belgium, Netherlands, Portugal, Denmark
Biogen

Completed

Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (MOBILE)

Multiple Sclerosis

Sweden, United Kingdom, Netherlands, Belgium, Canada, Italy
Biogen

Terminated

Fampridine Pregnancy Exposure Registry

Multiple Sclerosis | Pregnancy

France
Carmel Medical Center

Completed

Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis

Multiple Sclerosis

Israel
University of Zurich

Unknown

Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis (FAMPKIN)

Multiple Sclerosis

Switzerland
Vestre Viken Hospital Trust

Unknown

Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis

Multiple Sclerosis | EDSS 4-7

Norway
Biogen
Acorda Therapeutics

Completed

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Healthy

Hong Kong, Australia
Biogen
Acorda Therapeutics

Completed

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Multiple Sclerosis

Canada

3

Subscribe